Melanoma Research Victoria

Source: Medwire News, December 2018 medwireNews: An updated analysis of the CheckMate 067 trial shows continued survival benefits at 4 years with nivolumab plus ipilimumab or nivolumab monotherapy versus ipilimumab alone in patients with previously untreated advanced melanoma. The study findings are published in The Lancet Oncology and were also presented at the ESMO 2018 Congress in Munich, Germany. For the […]

Read the full story

Source: Healio, December 2018 NEW YORK — The addition of spartalizumab to dabrafenib and trametinib appeared safe and effective for previously untreated patients with advanced BRAF V600-mutant unresectable or metastatic melanoma, according to study results presented at Chemotherapy Foundation Symposium. All nine evaluated patients achieved a confirmed response. In addition, the safety profile for the triplet regimen […]

Read the full story

Source: Medical Express, December 2018 Susan M. Swetter, M.D., from Stanford University Medical Center in California, and colleagues reviewed the evidence and made treatment recommendations for patients with primary cutaneous melanoma. The researchers note that surgical excision is still the primary treatment modality for melanoma, while Mohs surgery or other forms of staged excision may […]

Read the full story

Source: Eurek Alert, December 2018 While studying a rare genetic disorder called NGLY1 deficiency, University of North Texas Health Science Center (UNTHSC) researchers discovered a new targeted treatment for combating melanoma, a skin cancer that kills about 9,000 people in the United States each year. Their research was recently published in the British Journal of Cancer. […]

Read the full story